Physician profile
Thomas J Edd
NPI 1538514864
$3,812.14
in general payments reported to CMS, 2019-2025
22 companies · $1,826 in 2025
The $1,826 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $12.94 · 2022: $126 · 2023: $522 · 2024: $1,123 · 2025: $1,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,355 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,355.32 |
| Education | $115.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $655.29 | 2024-2025 | Airsupra, Fasenra, Tezspire |
| Actelion Pharmaceuticals US, INC. | $585.12 | 2023-2025 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $567.66 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Grifols USA, LLC | $362.50 | 2024-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $350.53 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.48 | 2024-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $165.22 | 2024-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $160.78 | 2019-2025 | Winrevair |
| Acorda Therapeutics, INC | $102.40 | 2019 | |
| Viatris Specialty LLC | $84.32 | 2025 | Yupelri |
| Insmed, INC. | $78.94 | 2024-2025 | Arikayce, Brinsupri |
| Electromed, INC. | $65.80 | 2024-2025 | Smartvest |
| Amgen INC. | $58.97 | 2025 | Tezspire |
| United Therapeutics Corporation | $50.19 | 2024-2025 | Tyvaso, Tyvaso |
| Inogen, INC. | $49.11 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $47.07 | 2020-2023 | Xarelto |
| Mylan Specialty L.P. | $43.77 | 2024 | Yupelri |
| Ani Pharmaceuticals, INC. | $20.29 | 2025 | Purified Cortrophin Gel |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.19 | 2023 | Lifevest |
| Fujifilm Healthcare Americas Corporation | $19.49 | 2024 | Fujifilm |
| Vifor Pharma, INC. | $19.02 | 2024 | Veltassa |
| Verona Pharma, INC. | $19.00 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Edd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.